

112 chemotherapy-naïve patients were randomized to receive four to six 3-week cycles of taxane and platinum alone (n = 37) or taxane and platinum plus 0.20 mg/kg subcutaneous CPG 7909 on weeks 2 and 3 of each cycle (n = 75). Baseline demographics were similar for the treatment arms; however, 85% of patients in the CPG 7909 arm had stage IV NSCLC, vs. 65% in the chemotherapy-only arm. The phase II trial was conducted at 23 sites, and patients received study treatment until disease progression or unacceptable toxicity occurred. Primary endpoint was objective response rate (ORR), which was evaluated after cycles 2, 4, and 6 using Response Evaluation Criteria in Solid Tumors guidelines. Coded and blinded CT scans from 91 of 112 patients underwent retrospective independent radiological review. Ongoing secondary efficacy analyses include clinical benefit, time to response, duration of response, and survival; biomarker responses to CPG 7909 will be compared for responders and nonresponders in both arms.

Results: Data were available on all 112 patients for intention-to-treat response analysis. Investigator-evaluated ORR was 19% in the chemotherapy-only arm and 37% in the CPG 7909 arm; independent radiological review ORR was 25% vs. 32%, respectively. Median overall survival was 6.8 months in the chemotherapy-only arm and 11.7 months in the CPG 7909 arm, and Kaplan-Meier curves showed a trend toward improved overall survival in the latter arm. One-year survival rates were 36% vs. 47% in the chemotherapy-only and CPG 7909 arms, respectively. Survival analysis is ongoing.

Conclusions: The data suggest that addition of weekly CPG 7909 to a taxane/platinum regimen for first-line treatment of NSCLC improves objective response. Confirmatory phase III trials are warranted to further document the clinical benefit of this new agent.

1132

POSTER

Neoadjuvant and adjuvant chemotherapy in a radical treatment protocol for malignant mesothelioma with extrapleural pneumonectomy

A. Conybeare¹, J. Edwards¹, D. Stewart¹, K. O'Byrne², D. Waller¹.

¹Glenfield Hospital, Department of Thoracic Surgery, Leicester, United Kingdom; ²St James' Hospital, HOPE Directorate, Dublin, Republic of Ireland

Background: To evaluate the feasibility and effects of neoadjuvant and adjuvant chemotherapy as part of a radical surgery protocol for malignant mesothelioma (MM).

Materials and Methods: Case notes were analysed from 95 consecutive patients undergoing extrapleural pneumonectomy (EPP) for MM. Patients with non-sarcomatoid mesothelioma, clinically staged T1-3, N0-1, were resected if they were medically operable by standard criteria. Case notes were reviewed to determine how many successfully completed the planned tri-modality treatment programme, including chemotherapy and radiotherapy. The reasons for non-compliance were recorded. Differences in survival between groups were estimated using Kaplan-Meier analysis and the Log Rank test.

Results: Referrals were received from 28 oncology centres nationwide. Overall median survival from diagnosis was 14.7 months for all patients and 28.9 months for epithelioid node negative cases. Neoadjuvant chemotherapy was administered to 20 patients, all of whom underwent successful EPP. Referral to an oncologist to consider adjuvant chemotherapy was made in 41 patients; treatment within 3 months was received by 8 patients. 8 died prior to assessment for adjuvant therapy and a further 7 were considered too unwell. However adjuvant chemotherapy was not offered to 10 patients as there was no residual disease. 3 patients refused adjuvant therapy and 2 were refused therapy as it was too long post operation. Overall survival in the patients receiving neoadjuvant or adjuvant chemotherapy was greater than those not receiving chemotherapy (p = 0.005). In multivariate analysis, significant independent prognostic factors were the receipt of neoadjuvant or adjuvant chemotherapy (p = 0.02) and preoperative haemoglobin >14 g/dL (p = 0.04).

Conclusions: Survival in patients receiving chemotherapy as well as EPP was greater than surgery alone. The success rate at achieving adjuvant chemotherapy was low, therefore we advocate incorporation of neoadjuvant chemotherapy in future trials.

1133

POSTER

Phase I/II dose-escalation trial of patupilone every 3 weeks in patients with non-small cell lung cancer

J.M. Sánchez¹, K. Østerlind², P. Zatlouka³, J. Hamm⁴, C.P. Belani⁵, E. Kim⁶, E. Felip⁷, M. Berton⁸, I. Sklenar³, A. Johri⁹. ¹Hospital Germans Trias i Pujol, Servicio de Oncología, Barcelona, Spain; ²Finsencentret, Rigshospitalet, København, Denmark; ³University Hospital Na Bulovce, Prague, Czech Republic; ⁴Norton Healthcare/Hospital Inc., Louisville, KY, USA; ⁵University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA; ⁶The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA; ⁷Vall d'Hebron University Hospital, Barcelona, Spain; ⁸Novartis Pharma AG, Basel, Spain; ⁹Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

Background: Although the current standard of care for patients with newly diagnosed advanced non-small cell lung cancer (NSCLC) is a platinum-containing doublet, these regimens are associated with cumulative toxicity and suboptimal survival. Patupilone, a natural epothilone, is a microtubule-targeting cytotoxic agent that is active in a variety of tumors, including those that are resistant to taxanes. We are investigating the safety, efficacy, and maximum tolerated dose of patupilone in patients with stage IIIB/IV NSCLC.

Material and Methods: Patients who did not have brain metastases, who had relapsed after 1 prior platinum-containing regimen, and who had good performance status were enrolled. Patients received patupilone at a starting dose of 6.5 mg/m² via 20-minute IV infusion once every 3 weeks, with dose escalation in 0.5 mg/m² increments and proactive diarrhea management in the phase I study. Any grade 3 or 4 toxicities occurring in cycle 1 were considered dose-limiting toxicities.

Results: To date, 50 patients have been enrolled in 13 cohorts receiving 6.5 (n = 3), 7.0 (n = 3), 7.5 (n = 6), 8.0 (n = 6), 8.5 (n = 6), 9.0 (n = 3), 9.5 (n = 3), 10.0 (n = 3), 10.5 (n = 3), 11.0 (n = 3), 11.5 (n = 3), 12.0 (n = 3), and 13.0 (n = 5) mg/m² patupilone. All patients had received platinum therapy and 30% had been treated with a taxane. Median age was 59 years (range, 33 to 77 years) and median performance status was 1. Dose-limiting toxicities were observed in 4 patients: 1 patient in the 7.5 mg/m² cohort reported grade 3 asthenia and 3 patients (1 patient each in the 8.0-, 8.5-, and 13.0 mg/m² cohorts) reported grade 3 diarrhoea. The most frequently reported adverse events were diarrhoea (60%), nausea (40%), and abdominal pain (34%). Of 17 patients who had grade 3 adverse events; 7 had grade 3 diarrhoea. Grade 1 or 2 peripheral neuropathy occurred in 12 patients and grade 3 peripheral neuropathy occurred in 3 patients. Grade 1 alopecia occurred in 6 patients. Grade 3 hematologic toxicity was rare, and there were no grade 4 adverse events. Based on acute and chronic toxicities, the recommended phase II dose is 10 mg/m² patupilone. Five patients had a partial response (including 1 prior taxane-treated patient) and 14 patients had stable disease according to Response Evaluation Criteria in Solid Tumors.

Conclusion: Patupilone is safe and well tolerated and may have antitumor activity in patients with advanced NSCLC. Updated data will be presented.

1134

POSTER

A randomized phase II trial of irinotecan plus carboplatin versus etoposide plus carboplatin in patients with extensive disease small cell lung cancer

A. Schmitt¹, L. Fischer von Weikersthal², M. Sebastian³, K. Schulze⁴, H. Link⁵, E. Thiel¹, U. Keilholz¹. ¹Charité, Campus Benjamin Franklin, Dept. of Hematology and Oncology, Berlin, Germany; ²St. Marien Hospital, Dept. of Hematology and Oncology, Amberg, Germany; ³University of Mainz, Dept. of Pulmology, Mainz, Germany; ⁴Charité, Campus Benjamin Franklin, Dept. of Cardiology and Pulmology, Berlin, Germany; ⁵Westfal-Clinics, Dept. of Hematology and Oncology, Kaiserslautern, Germany

Background: Superiority of irinotecan/cisplatin over etoposide/cisplatin has been demonstrated in a small phase III trial in extensive disease small cell lung cancer (SCLC). Since carboplatin is as effective as cisplatin with a favourable toxicity profile, many oncologists prefer carboplatin. The trial presented here analyzed the efficacy of irinotecan/carboplatin (IP) versus the standard regimen etoposide/carboplatin (EP).

Patients and Methods: Extensive disease SCLC patients were randomly assigned to receive carboplatin AUC 5 mg x min/mL either in combination with 50 mg/m² of irinotecan on days 1, 8 and 15 (IP) or with etoposide 140 mg/m² days 1-3 (EP). Cycles were repeated on day 29 in arm A (IP) and on day 22 in arm B (EP). The trial was designed as a phase III study with OS as primary endpoint. After a first step of 70 patients it was planned to perform a phase II analysis to determine response rate and toxicity before extension into phase III.